New oral drug targets Cancer's growth engine in advanced tumours

NCT ID NCT03096054

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial investigates an experimental oral drug, LY3143921 hydrate, which blocks a protein called Cdc7 that cancer cells need to divide. It is being tested in adults with advanced solid tumours, including colorectal, ovarian, lung, and pancreatic cancers, that have not responded to standard treatments. The main goals are to find the safest dose and understand the drug's side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an oral drug called LY3143921 hydrate that blocks a protein (Cdc7) involved in cancer cell growth
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumours that have stopped responding to standard therapies.
What could go wrong
This is an early phase I trial with a small number of participants, so the drug may not prove effective or may have significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE TYPE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beatson West of Scotland Cancer Centre

    Glasgow, G12 0YN, United Kingdom

  • Northern Centre for Cancer Care

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Northern Ireland Cancer Centre

    Belfast, BT9 7JL, United Kingdom

  • Western General Hospital

    Edinburgh, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.